List of Airsupra drug patents

Airsupra is owned by Bond.

Airsupra contains Albuterol Sulfate; Budesonide.

Airsupra has a total of 1 drug patent out of which 0 drug patents have expired.

Airsupra was authorised for market use on 10 January, 2023.

Airsupra is available in aerosol, metered;inhalation dosage forms.

Airsupra can be used as as-needed treatment or prevention of bronchoconstriction and reduction of the risk of exacerbations in patients with asthma 18 years of age and older.

The generics of Airsupra are possible to be released after 28 May, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415009 BOND Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(7 years from now)

Do you want to check out AIRSUPRA patents from before 2022?
Exclusivity Exclusivity Expiration
New Product (NP) Jan 10, 2026

Drugs and Companies using ALBUTEROL SULFATE; BUDESONIDE ingredient

Market Authorisation Date: 10 January, 2023

Treatment: As-needed treatment or prevention of bronchoconstriction and reduction of the risk of exacerbations in patients with asthma 18 years of age and older

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

AIRSUPRA family patents

26

United States

10

Japan

9

Taiwan

8

Lithuania

8

Hungary

7

Russia

7

Korea, Republic of

7

Australia

6

Spain

6

Hong Kong

6

Denmark

6

Poland

6

China

6

Argentina

6

Croatia

6

Portugal

6

Slovenia

6

European Union

5

Cyprus

4

Mexico

3

Brazil

3

Canada

3

Ukraine

3

San Marino

3

Israel

3

South Africa

2

Norway

2

Luxembourg

1

Philippines

1

ME

1

Netherlands

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in